Infectious Disease · Pediatrics ·
French study finds low EV-A71 antibody prevalence in infants
A seroprevalence study of 501 children and adolescents in metropolitan France found neutralising antibodies in 43.7% for EV-A71 and 96.0% for EV-D68. Most children under 1 year lacked EV-A71 antibodies, although the study measured antibodies rather than clinical outcomes.
- EV-A71 seroprevalence was 43.7%; EV-D68 was 96.0%.
- Twenty-three of 25 infants lacked EV-A71 protective antibodies.
- EV-A71 seropositivity varied by age and geographical area.
- The study measured antibodies, not clinical outcomes.
Researchers used stratified sampling to examine 501 serum samples from people aged 0–17 years in metropolitan France, collected between 2023 and 2025. Neutralising antibodies were tested against EV-A71 sub-genogroup C1 and EV-D68 subclade B3 strains isolated in 2016; estimates were analysed by sex, age group and geographical area.
Estimated seroprevalence was 43.7% for EV-A71 (95% CI 39.3–48.2) and 96.0% for EV-D68 (95% CI 93.9–97.5). EV-A71 seropositivity varied by age and area, while no sex differences were observed. Of 25 children younger than 1 year, 23 lacked EV-A71 protective antibodies. Antibody titres differed across age groups for both viruses.
The findings indicate substantial serological susceptibility to EV-A71 among the youngest children in this French sample, in contrast with high EV-D68 seroprevalence. Seropositivity is an antibody measure, not a clinical outcome; the study does not establish individual risk of severe disease. Results are based on samples from metropolitan France and the specific viral strains tested.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Eurosurveillance: Seroprevalence of EV-A71 and EV-D68 antibodies in the paediatric and adolescent population, France, 2023 to 2025 ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.